Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) was downgraded by research analysts at StockNews.com from a "hold" rating to a "sell" rating in a research note issued on Thursday.
Several other brokerages also recently issued reports on ABEO. HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a research note on Monday, November 25th. Cantor Fitzgerald reissued an "overweight" rating and issued a $18.00 price target on shares of Abeona Therapeutics in a research report on Tuesday, October 29th.
Check Out Our Latest Stock Analysis on ABEO
Abeona Therapeutics Trading Down 0.7 %
NASDAQ ABEO traded down $0.04 on Thursday, hitting $5.96. 176,742 shares of the stock were exchanged, compared to its average volume of 266,048. The company's 50-day moving average price is $5.97 and its two-hundred day moving average price is $5.64. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. Abeona Therapeutics has a 52-week low of $3.05 and a 52-week high of $9.01. The company has a market capitalization of $259.09 million, a price-to-earnings ratio of -2.22 and a beta of 1.46.
Institutional Trading of Abeona Therapeutics
A number of institutional investors have recently bought and sold shares of the company. Jane Street Group LLC acquired a new position in Abeona Therapeutics in the 3rd quarter worth about $84,000. Charles Schwab Investment Management Inc. acquired a new position in Abeona Therapeutics in the third quarter worth approximately $151,000. XTX Topco Ltd acquired a new position in Abeona Therapeutics in the third quarter worth approximately $160,000. JPMorgan Chase & Co. raised its position in Abeona Therapeutics by 74.2% during the third quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company's stock valued at $424,000 after acquiring an additional 28,606 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Abeona Therapeutics by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company's stock valued at $515,000 after acquiring an additional 2,434 shares during the last quarter. Institutional investors and hedge funds own 80.56% of the company's stock.
Abeona Therapeutics Company Profile
(
Get Free Report)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Abeona Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.
While Abeona Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
